Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
https://doi.org/10.17709/410-1893-2023-10-3-8
EDN: HLGXND
Abstract
Treatment of patients with metastatic castration-resistant prostate cancer in clinical practice is a vital necessity and a challenging task since the causes of castration resistance are not fully understood. Adherence to treatment regimens in accordance with the National Clinical Guidelines allows to achieve an increase in both overall survival and progression-free survival, as well as to reduce the mortality rate in this category of patients. Administration of 1st-line treatment regimens stabilizes the disease in the majority of pancreatic cancer patients; in some cases, the disease becomes aggressive, distant metastases appear, most oſten in bones, lymph nodes, and internal organs, as demonstrated by three clinical observations presented in this article. The administration of enzalutamide (in 2 cases) and abiraterone acetate (in 1 case) at the stage of resistance to castration therapy allowed to obtain a complete “response” from visceral lesions, stabilise bone metastatic foci and increase the life expectancy of patients.
About the Authors
P. G. Berezin
Tambov Regional Oncological Clinical Dispensary
Russian Federation
Competing Interests:
Russian Federation
Petr G. Berezin – MD, Oncourologist, Tambov Regional Oncological Clinical Dispensary, Tambov, Russian Federation
ORCID: https://orcid.org/0000-0002-3229-6884, SPIN: 5445-4506, AuthorID: 1084266, Scopus Author ID: 57208280280
Competing Interests:
The authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article.
V. V. Milovanov
Tambov Regional Oncological Clinical Dispensary
Russian Federation
Competing Interests:
Russian Federation
Vladimir V. Milovanov – Chief Physician, Tambov Regional Oncological Clinical Dispensary, Tambov, Russian Federation
SPIN: 5970-7170, AuthorID: 934565, Scopus Author ID: 56235806200
Competing Interests:
The authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article.
A. A. Ivannikov
Tambov Regional Oncological Clinical Dispensary
Russian Federation
Competing Interests:
Russian Federation
Andrei A. Ivannikov – Chief Substitute of Medical Office, Tambov Regional Oncological Clinical Dispensary», Tambov, Russian Federation
Competing Interests:
The authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article.
V. A. Kuleshkov
S. S. Bryukhonenko City Hospital
Russian Federation
Competing Interests:
Russian Federation
Vladimir А. Kuleshov – Chief Physician of S. S. Bryukhonenko City Hospital, Michurinsk, Tambov Region, Russian Federation
Competing Interests:
The authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article.
K. M. Nyushko
Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiologiсal Center
Russian Federation
Competing Interests:
Russian Federation
Kirill M. Nyushko – Dr. Sci. (Medicine), Professor, Leading Researcher at the Department of Oncourology, Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russian Federation
ORCID: https://orcid.org/0000-0002-4171-6211, SPIN: 7162-5527, AuthorID: 651466, Scopus Author ID: 56901354500
Competing Interests:
The authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article.
References
1. Kostin AA, Kulchenko NG, Tolkachev AO. Forecasting the development of cancer of prostate. Multidisciplinary approach. Bulletin of the Medical Institute “REAVIZ” (Rehabilitation, Doctor and Health). 2017;1(25):60 –67. (In Russ.).
2. Kostin AA, Kulchenko NG, Tolkachev AO. Prostate cancer. Principles of early diagnosis. RUDN Journal of Medicine. 2016;4:68–76. (In Russ.).
3. The state of oncological care of the Russian population in 2019. Edited by Kaprin AD, Starinsky V.V, Shakhzadova A.O. Moscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2020, 236 p. (In Russ.). Available at: https://glavonco.ru/cancer_register/Помощь%202019.pdf. Accessed: 10.05.2023.
4. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Edited by Kaprin AD, Starinsky VV, Shakhzadova AO. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2020, 252 p. (In Russ.). Available at: https://glavonco.ru/cancer_register/Забол_2019_Электр. pdf. Accessed: 10.05.2023.
5. Clinical recommendations for prostate cancer. Moscow: Ministry of Health of the Russian Federation. 2021, 136 p. (In Russ.). Available at: https://oncology-association.ru/wp-content/uploads/2021/02/rpzh.pdf. Accessed: 10.05.2023.
6. Alekseyev BY, Nyushko KM. Intermittent hormone therapy in patients with prostate cancer. Cancer Urology. 2011;7(4):12 – 15. (In Russ.). https://doi.org/10.17650/1726-9776-2011-7-4-12-15
7. Pavlov AYu, Agafonov RA, Tsybulsky AD, Fastovets SV, Kravtsov IB. Modern strategy of drug therapy of metastatic and castration-resistant prostate cancer. RMJ (Russian Medical Journal). 2016;8:476–479. (In Russ.).
8. Matveev VB, Khalmurzaev OA, Evsyukova OI. International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review. Cancer Urology. 2020;16(4):197–206. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-4-197-206
9. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180–1192. https://doi.org/10.1111/j.1742-1241.2011.02799.x
10. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080–1087. https://doi.org/10.1200/jco.2017.75.3657
11. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163–1177. https://doi.org/10.1016/s0140-6736(15)01037-5
12. Tombal B. Enzalutamide in men with chemotherapy neive metastatic castration- resisant prostatcancer (mCRPC): Final overall survival analysis at the fase 3 PREVAIL Study 2015. Presented at the 2015 EAU Congress, Madrid, Spein; 28 April 2015.
13. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 May;20(5):686–700. https://doi.org/10.1016/s1470-2045(19)30082-8
14. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov;15(12):1397–406. https://doi.org/10.1016/s1470-2045(14)70474-7
15. Alekseev BY, Nyushko KM, Reva SA, Nosov AK, Prokhorov DG, Andabekov TT, et al. Salvage lymphadenectomy in patients with lymphogenic prostate cancer progression aſter radical treatment: results of a multicenter study. Cancer Urology. 2016;12(4):70–80. (In Russ.). https://doi.org/10.17650/1726-9776-2016-12-4-70-80
Review
For citations:
Berezin P.G., Milovanov V.V., Ivannikov A.A., Kuleshkov V.A., Nyushko K.M. Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region. Research and Practical Medicine Journal. 2023;10(3):86-96. (In Russ.) https://doi.org/10.17709/410-1893-2023-10-3-8. EDN: HLGXND
Views:
262
Email this article 